Idiopathic pulmonary fibrosis (IPF) is the clinical syndrome and is considered the most common and most lethal form of pulmonary fibrosis corresponds to the histologic and imaging pattern of UIP; it is more common in middle age or elderly men and diagnosed by:
- histological or imaging pattern of usual interstitial pneumonia (UIP) and
- absence of alternative causes such as drug toxicity, environmental exposure (e.g. asbestos) or collagen vascular disease (e.g. scleroderma, rheumatoid arthritis)
It tends to be commoner in males with most cases presenting in those over 50 years of age.
Patients typically present with progressive dyspnea on exertion and chronic dry cough, finger clubbing, chest pain, fatigue, malaise, and weight loss. Pulmonary function test results may be normal in mild disease or shows restriction pattern (i.e. reduced vital capacity and total lung capacity but near normal residual volume). DLCO is commonly decreased even in with mild cases.
Multidisciplinary approach in tertiary setting is strongly advised. Contributions from pulmonists, chest radiologists, and chest pathologist are crucial reaching the correct diagnosis of IPF.
ATS/ERS (American Thoracic Society and European Respiratory Society) has developed major and minor criteria for the diagnosis of IPF in the absence of a surgical lung biopsy 5:
- exclusion of other known causes of interstitial lung disease (e.g. toxic effects of certain drugs, environmental exposures, connective tissue diseases) abnormal results of pulmonary function studies, including evidence of restriction (reduced vital capacity, often with an increased FEV1/FVC ratio) and impaired gas exchange (increased PaO2, decreased PaO2 with rest or exercise, or decreased DlCO)
- bibasilar reticular abnormalities with minimal ground-glass opacities at high-resolution CT: definite UIP pattern on HRCT chest
- transbronchial lung biopsy or bronchoalveolar lavage shows no features to support an alternative diagnosis
- age >50 years
- insidious onset of otherwise unexplained dyspnea on exertion
- duration of illness being over 3 months
- bibasilar inspiratory crackles (dry or “Velcro” type)
IPF as he name implies it is idiopathic however there is an association with concurrent or previous history of smoking in 60% of patients and genetic factors; up to 5–20% of patients with IPF have a family history of ILD or pulmonary fibrosis.
The rs35705950 single-nucleotide polymorphism (SNP)—a promoter site of an airway mucin gene (MUC5B)—is strongly associated with IPF and familial pulmonary fibrosis and not seen in other secondary causes of lung fibrosis. Positive rs35705950 SNP in IPF patients is associated with slightly better prognosis and outcome.
Histology shows UIP pattern which is characterized by spatial and temporal heterogeneity. Spatial heterogeneity denotes biopsy sample showing patchy lung involvement with normal lung interspace between diseased lung. Temporal heterogeneity denotes different stages of disease seen on a single specimen, including normal lung, interstitial inflammation, interstitial fibrosis and fibroblastic foci 4.
The CT imaging findings complement the histology. It is more correct to describe characteristic imaging pattern as UIP rather than IPF, a terminology assigned for the idiopathic clinical syndrome of UIP.
A UIP-pattern of fibrosis is characterised by honeycombing cysts and reticular septal thickening with subpleural and posterior basal predominance. Traction bronchiectasis can also be observed, however, this is a general feature of fibrosis not specific to UIP-pattern 4. In a subgroup of patients the imaging finding of UIP overlap with NSIP and biopsy may be necessary to obtained the correct diagnosis.
Treatment and prognosis
The clinical course is that of gradual deterioration and the condition carries a rather poor prognosis with median survival ranging from 2.5 to 3.5 years from the time of diagnosis (at the time of initial writing) 2. Some reports have suggested a slowing of progression with treatment by Pirfenidone 7-8.
Consider pulmonary fibrosis due to a known cause, such as:
- 1. Wittram C, Mark EJ, Mcloud TC. CT-histologic correlation of the ATS/ERS 2002 classification of idiopathic interstitial pneumonias. Radiographics. 23 (5): 1057-71. doi:10.1148/rg.235035702 - Pubmed citation
- 2. Souza CA, Müller NL, Flint J et-al. Idiopathic pulmonary fibrosis: spectrum of high-resolution CT findings. AJR Am J Roentgenol. 2005;185 (6): 1531-9. doi:10.2214/AJR.04.1599 - Pubmed citation
- 3. Lynch DA, Godwin JD, Safrin S et-al. High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. Am. J. Respir. Crit. Care Med. 2005;172 (4): 488-93. doi:10.1164/rccm.200412-1756OC - Pubmed citation
- 4. Mueller-mang C, Grosse C, Schmid K et-al. What every radiologist should know about idiopathic interstitial pneumonias. Radiographics. 27 (3): 595-615. doi:10.1148/rg.273065130 - Pubmed citation
- 5. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am. J. Respir. Crit. Care Med. 2002;165 (2): 277-304. Am. J. Respir. Crit. Care Med. (link) - Pubmed citation
- 6. du Bois RM, Wells AU. Cryptogenic fibrosing alveolitis/idiopathic pulmonary fibrosis. Eur Respir J Suppl. 2002;32: 43s-55s. Pubmed citation
- 7. Noble PW, Albera C, Bradford WZ et-al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377 (9779): 1760-9. doi:10.1016/S0140-6736(11)60405-4 - Pubmed citation
- 8. Taniguchi H, Ebina M, Kondoh Y et-al. Pirfenidone in idiopathic pulmonary fibrosis. Eur. Respir. J. 2010;35 (4): 821-9. doi:10.1183/09031936.00005209 - Pubmed citation
- 9. Chung J, Lynch D. American Journal of Roentgenology. 2016;206 (3): . doi:10.2214/AJR.15.15627
- 10. Gruden J. American Journal of Roentgenology. 2016;206 (3): . doi:10.2214/AJR.15.15674